What question did this study set out to answer?

Summarize whether GLP-1 receptor agonists increase the risk of pancreatitis, pancreatic malignancy, and thyroid C-cell neoplasms.

July 17, 2013Diabetes CareOpen Access

Do GLP-1–Based Therapies Increase Cancer Risk?

View Full Paper

Ask AI

Bookmark

Summarize whether GLP-1 receptor agonists increase the risk of pancreatitis, pancreatic malignancy, and thyroid C-cell neoplasms.
Reviewed clinical reports of pancreatitis associated with glucagon-like peptide-1 receptor agonists, specifically exenatide and liraglutide.
Analyzed rodent experimental models evaluating thyroid C-cell calcitonin secretion and adenoma formation following long-term receptor stimulation.
Clinical evidence links exenatide and liraglutide with pancreatitis, establishing a potential mechanistic pathway to chronic pancreatitis and subsequent pancreatic cancer.
Prolonged GLP-1 receptor stimulation in rodents elevates cAMP and induces calcitonin release in thyroid C cells, resulting in C-cell hyperplasia and adenoma formation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Narrative review examines pancreatic and thyroid cancer risks in animal models and patients, highlighting cellular mechanisms that promote abnormal proliferation.

Cite This Study

Nauck et al. (2013) studied this question.

synapsesocial.com/papers/6a1bc0fdc97d63156a5ee036 https://doi.org/10.2337/dcs13-2004

View Full Paper

Ask AI

Bookmark

Implication

Narrative review examines pancreatic and thyroid cancer risks in animal models and patients, highlighting cellular mechanisms that promote abnormal proliferation.

Do GLP-1–Based Therapies Increase Cancer Risk?

Key Points

Discussion

Implication

Cite This Study

Do GLP-1–Based Therapies Increase Cancer Risk?

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider